Denali Therapeutics Inc.
Disclosed SEC business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
Denali Therapeutics Inc. (ticker DNLI, CIK 0001714899) is tracked by Global Barry from its public SEC filings and disclosures. Disclosed industry classification: Biological Products, (No Diagnostic Substances) (SIC 2836). Disclosed business address country: United States. Every item is grounded on the cited public source — no figures are fabricated.
Go deeper
This is the free public preview. Open the deeper, source-linked evidence detail and the full in-app workspace. You have 5 free company deep views left this month.
Sources
- U.S. Securities and Exchange Commission, EDGAR · XBRL company facts · retrieved 2026-10-24T19:19:50.687789+00:00
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-02T10:46:52.262627+00:00
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-02T10:46:56.271188+00:00
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-02T10:47:00.383900+00:00
Grounded on public SEC filings and disclosures with explicit evidence tiers and citations. This page is informational only and is not investment advice. No figures are fabricated; unavailable data is shown as unavailable.